Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobus Pfisterer

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJacobus Pfisterer, Marie Plante, Ignace Vergote, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|December 28, 2023
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancerAndreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovaryAikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
First-line therapy in ovarian cancer trialsTate Thigpen, Andreas duBois, Jessica McAlpine, et al.
British Journal of Cancer|April 1, 2022
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor eraBenoit You, Lilian Van Wagensveld, Michel Tod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice VariantPauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
Human Pathology|May 4, 2020
Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinomaBasile Tessier-Cloutier, Dawn R Cochrane, Anthony N Karnezis, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJacobus Pfisterer, Marie Plante, Ignace Vergote, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|December 28, 2023
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancerAndreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovaryAikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
First-line therapy in ovarian cancer trialsTate Thigpen, Andreas duBois, Jessica McAlpine, et al.
British Journal of Cancer|April 1, 2022
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor eraBenoit You, Lilian Van Wagensveld, Michel Tod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice VariantPauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
Human Pathology|May 4, 2020
Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinomaBasile Tessier-Cloutier, Dawn R Cochrane, Anthony N Karnezis, et al.
Pageof 10